Running for the Exits
from Massachusetts Biotechnology Council
This event has passed.
Tuesday, June 24, 2008, 8:00am - 10:00am
The uncertainty in the public markets reinforces the need to think and plan for an exit under multiple scenarios.
Join us on Tuesday June 24th as Jaime Burns, Director, Healthcare Investment Banking, Credit Suisse , Glen Giovannetti, Global Biotechnology Leader of Ernst & Young , John McCarthy, SVP and CFO of Verenium, and David Redlick, co-chair of the Life Sciences group at WilmerHale , discuss the current state of the IPO and M&A markets and offer their advice and counsel on how best to plan and achieve a well-timed exit.
Topics:
- Factors to consider in planning for IPO's and M&A's
- Does a company grow and plan differently if they assume one exit versus the other?
- The importance of timing and market positioning
- When to start planning for an IPO or a merger
- Are various overseas markets a viable IPO option - AIM, EuroNext, Australia, etc.?
- What will it take for the IPO market to open again domestically and when do we think it will happen?
- How does a weaker dollar impact potential IPO or M&A transactions?
Speakers:
- Glen Giovannetti, Partner and Global Biotechnology Leader , Ernst & Young
- John A. McCarthy, Jr., Executive Vice President and Chief Financial Officer, Verenium
- David Redlick, co-chair of the Life Sciences Group , WilmerHale
More information...
Pingbacks ( Use this URL to link to this event: http://www.marksguide.com/event/2286/ )
